Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	
Xero Limited	
ABN	
160 661 183 (ARBN)	
, ,	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 *Class of *securities issued or to be issued
- (a) Ordinary Shares
- (b) Conditional Agreement to issue Ordinary Shares in Xero Limited (**Restricted Stock Units** or **RSUs**)
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- (a) 487,510 Ordinary Shares
- (b) 270,554 RSUs relating to the future issue of up to 270,554 Ordinary Shares

- 3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; ⁺convertible securities, the conversion price and dates for conversion)
- (a) 485,526 fully paid Ordinary Shares were issued in accordance with the Rules of the Xero Limited Employee Restricted Share Plan as part of the remuneration package of employees based in New Zealand, Australia and the United Kingdom. Participating employees will become entitled to the shares in specified percentages over the course of the next two to three years (on 31 March 2016, 2017 and 2018, as applicable), subject to the terms of the Xero Limited Employee Restricted Share Plan, including continued employment of the relevant participating employee with the Xero Limited Group on each vesting date; 1,984 fully paid Ordinary Shares were issued to Lee Hatton at an issue price equal to NZ\$17.64, being the 20 day volume weighted average market price of Xero Limited's Ordinary Shares on the NZX Main Board through to 7 August 2015
- (b) 215,113 RSUs have been granted pursuant to the Xero Limited (USA) Equity Incentive Scheme as part of the remuneration package of US based employees. The number of RSUs granted was calculated based on the total dollar entitlement of all eligible employees divided by NZ\$17.64, being the 20 day volume weighted average market price of Xero Limited's Ordinary Shares on the NZX Main Board through to 7 August 2015. The RSUs will "vest" (meaning that an equivalent number of Ordinary Shares in Xero Limited will be issued) (Vest) in equal percentages over the next three years (on 31 March 2016, 2017 and 2018), subject to the terms of the Xero Limited (USA) Equity Incentive Scheme, including the continued employment of the relevant participating employee with the Xero Limited Group on each vesting date
- 50,126 RSUs have been granted pursuant to the Xero Limited (USA) Equity Incentive Scheme. The RSUs will Vest in accordance with the terms of each key executive employee's RSU Agreement and the terms of the Xero Limited (USA) Equity Incentive Scheme, including continued employment of the relevant employee with the Xero Limited Group, and, where applicable, the satisfaction of certain performance hurdles, on each vesting date
- 5,315 RSUs have been granted pursuant to the Xero Limited Restricted Stock Unit Plan (NZ) as part of the remuneration package of a key executive employee based in NZ. The number

⁺ See chapter 19 for defined terms.

of RSUs granted is calculated based on the total dollar entitlement of the eligible key employee divided by NZ\$17.64, being the 20 day volume weighted average market price of Xero Limited's Ordinary Shares on the NZX Main Board through to 7 August 2015. The RSUs will Vest in equal percentages over the next three years (on 31 March 2016, 2017 and 2018), subject to the terms of the Xero Limited Restricted Stock Unit Plan (NZ), including the continued employment of the relevant participating employee with the Xero Limited Group on each vesting date

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

- (a) Yes
- (b) N/A

- (a) NZ\$17.64 per Ordinary Share, being the 20 day volume weighted average market price of Xero Limited's Ordinary Shares on the NZX Main Board through to 7 August 2015
- (b) RSUs were granted at a value of NZ\$17.64 each, being the 20 day volume weighted average market price of Xero Limited's Ordinary Shares on the NZX Main Board through to 7 August 2015. No cash consideration is required to be paid for the RSUs to Vest

Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

- (a) 485,526 Ordinary Shares were issued under the Xero Limited Employee Restricted Share Plan as part of the remuneration package of employees based in New Zealand, Australia and the United Kingdom; 1,984 Ordinary Shares were issued to Lee Hatton, in lieu of cash, as remuneration for her role as a director of Xero Limited for the preceding six-month period, to a value of NZ\$35,000 (Lee Hatton's current total annual remuneration for her role as a director of Xero Limited is NZ\$70,000)
- (b) Grant of 265,239 RSUs pursuant to the Xero Limited (USA) Equity Incentive Scheme, and grant of 5,315 RSUs pursuant to the Xero Limited Restricted Stock Unit Plan (NZ), as part of the remuneration package of certain employees based in the United States and New Zealand, respectively

⁺ See chapter 19 for defined terms.

6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	N/A
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
C.L.	The data the equition helder	TAL/A
6b	The date the security holder resolution under rule 7.1A was passed	N/A
0-	Niverban of taxavities issued	DAL/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
		T.,,,
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
_		F
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under	N/A
OII	rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	IV/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A

7	⁺ Issue dates	(a) 10 August 201	5
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	(b) 10 August 201	5 (grant date)
	Cross reference: item 33 of Appendix 3B.		
		Number	⁺ Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (including the ⁺ securities in section 2 if applicable)	136,595,374	Ordinary
		Number	⁺ Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	647,222 RSUs	RSUs (a conditional contractual right to be issued up to 647,222 Ordinary Shares) – taking into account all forfeited RSUs to date
		555,862 Options	Unlisted Options (convertible into Ordinary Shares on a 1:1 basis)
10	Dividend policy (in the case of a trust, distribution policy) on the	(a) As for all Ordinary Sh	nares
	increased capital (interests)	(b) N/A	
Part	2 - Pro rata issue		
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	⁺ Class of ⁺ securities to which the offer relates	N/A	

⁺ See chapter 19 for defined terms.

15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their	N/A
	entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
		[N. 10
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the iccue is contingent an	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Data antitlement and	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	IV/A

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell part of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A
	t 3 - Quotation of section of section if you are the true of *securities (tick one) (in respect of the "Ordina throughout in paragraph "(a)	applying for quotation of securities ary Shares" described in Part 1 only, i.e. referenced
(b)		
Entities that have ticked box 34(a) Additional securities forming a new class of securities		

⁺ See chapter 19 for defined terms.

Tick to docum	o indicate you are providing the information or nents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Enti	ities that have ticked box 34(b)
38	Number of *securities for which *quotation is sought
39	⁺ Class of ⁺ securities for which quotation is sought
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41	now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	†Class
		Nullibei	Class
42	Number and +class of all		
	*securities quoted on ASX		
	(including the *securities in		
	clause 38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 11 August 2015

(Director/Company secretary)

Print name: Matt Vaughan

XX/01/2015 Appendix 3B Page 11

 $^{+\} See\ chapter\ 19\ for\ defined\ terms.$

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	
Add the following:	
 Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2 	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	
 Number of partly paid [†]ordinary securities that became fully paid in that 12 month period 	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	
"A"	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15		
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

XX/01/2015 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.

Part 2

ent capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
0.10		
Note: this value cannot be changed		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"		
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"		
	Note: this is the remaining placement capacity under rule 7.1A	

XX/01/2015 Appendix 3B Page 15

⁺ See chapter 19 for defined terms.